All news

Argus lifts Teva target to $50 on Buy rating

Alpha Vantage · TradingView · · AI-summarised by FinFlash

Argus Research kept its Buy rating on Teva Pharmaceutical and lifted its price target to $50 from $42, a 19% increase. The new target implies roughly 18.1% upside from the $42.57 share price. Analyst ratings stand at 12 Buy, 1 Hold and 0 Sell. DME Capital Management also disclosed a new Teva stake of 1,817,146 shares.

Read original source

TEVA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.